| BackgroundChronic insomnia has a negative impact on physical and mentall health.It also affects the occurrence,development and treatment of other diseases of patients.Most patients with chronic insomnia have poor stress coping systems,which can not effectively cope with stress,thus leading to anxiety.One study also showed that the incidence rate of anxiety in insomnia patients was 54%.Anxiety will not only aggravate the degree of insomnia,but also affect the curative effect of insomnia.Therefore,such patients are often more severe than simple insomnia in clinical practice,who have a longer course and are prone to recurrent attacks.Due to the limited implementation of psychological treatment in clinical work,using drugs are still the main treatment at present.Chemical medications commonly used for treatment include Benzodiazepines,anxiolytics,antidepressants,and so on.The efficacies of such drugs have been confirmed.But these drugs also cause some adverse reactions at the sametime,such as Benzodiazepines causing hangover,dependence,withdrawal and other symptoms.Traditional Chinese medicine(TCM),paying attention to overall condition,has less side effects.It can effectively improve insomnia and anxiety symptoms of patients,when TCM is combined with chemical medications.The method not only can quickly improve the symptoms of insomnia and anxiety in patients,but also exert the characteristics of adjusting the overall condition of TCM.Therefore,the combination of TCM and chemical medications in treating insomnia with anxiety is a worth topic to explore.ObjectiveThe trail is using AnshenPrescription combined with Lorazepam and Lorazepam alone to treat insomnia patients with anxiety.Through evaluating Pittsburgh Sleep Quality Index(PSQI),Selfrating Anxiety Scale(SAS),TCM syndrome scale,that could objectively evaluate the clnical effectiveness and safety of AnshenPrescription combined with Lorazepamin in treating insomnia patients with anxiety.Method68 insomnia patients were selected from Dongzhimen Hospital of Beijing University of Traditional Medicine and psychiatric clinic of Anjia Hospital of Huairou City in Beijing from January 2018 to October 2019.After excluding the missed cases,all patients were divided into the experimental group and the control group according to the ratio of 1:1.Finally there were 30 cases in each group.All objectives signed informed consent forms.The experimental group was orally administered with AnshenPrescription combined with Lorazepam,and the other group was orally given with Lorazepam.All patients were assessed and recorded with basic information(gender,age,course of disease,medication history,blood pressure,heartrate,etc.),PSQI,SAS,and TCM syndrome Scale on the day of admission.On the 14th and 28th day of treatment,the scores of all scales and adverse reactions were recorded.SPSS version22.0 was used to process the all statistical data.Result1.PSQIOn the 14th day and 28th day,there is no significant difference between the test group and the control group on the total scores of PSQI and the scores of 7 factors(P>0.05).On the 14th and 28th day,the total scores of PSQI in the two groups after treatment were lower than the scores before treatment,with significant difference(P<0.05).Except for the scores of using drugs,the scores of other items in the test group after treatment were significantly different from the scores before treatment(P<0.05).The scores of all items in the control group after treatment were significantly different from the scores before treatment(P<0.05).2.SASOn the 14th day and 28th day,the evaluation of SAS was carried out between the two groups.There is no significant difference between the two groups(P>0.05).On the 14th day and 28th day,the scores of SAS in two groups were compared.The scores after treatment in two groups were lower than the score before treatment,with significant difference(P<0.05).3.TCM syndrome scaleOn the 14th day and 28th day,the total scores of the test group were lower than that of the control group,with significant difference(P<0.05).On the 14th day,the score of dreaminess of the test group is significantly different from the score of the control group(P<0.05).On the 28th day,compared with the control group,there were significantly difference on the scores of dreaminess,hot flashes and night sweats,soreness and weakness of waist and knees of the test groups(P<0.05).On the 14th and 28th day,in comparison to the scores before treatment,the total scores of TCM syndrome scale after treatment in two groups were all lower,with significant difference(P<0.05).On the 14th day,except for dizziness,amnesia and tinnitus,the scores of the other items of the test group were significantly different from those before treatment(P<0.05).Except for dizziness,amnesia,tinnitus,hot flashes and night sweat,soreness of waist and knee,the scores of other items of the control group were significantly different from those before treatment(P<0.05).On the 28th day,the scores of all items in the test group were significantly different from those before treatment(P<0.05).Except for dizziness items,the scores of other items in the control group were significantly different from those before treatment(P<0.05).4.Clinical effective rateOn the 28th day of treatment,the two groups were calculated with PSQI score reduction rate.The clinical total effective rate of the experimental group was 63.33%.The clinical total effective rate of the control group was 46.67%.There was no significant difference between the two groups(P>0.05).Conclution1.Both AnshenPrescription combined with Lorazepam and Lorazepam can effectively decrease the scores of SAS and PSQI scale.The two groups have similar clinical effectiveness.2.The two therapies can effectively decrease the scores of TCM syndromes scale and improve some symptoms about TCM syndromes.The test group is better than the control group in improving TCM syndromes,especially dreaminess,soreness of waist and knees and hot flashes and night sweats.3.The clinical total effective rate of the test group is similar to the control group.4.There is no significant difference in the incidence of adverse reactions between two groups. |
PDF Full Text Request